To screen ETFs by asset class, performance, yield and more, check out the
Author Following Options:
Follow this author
See their articles on your Seeking Alpha homepage and in your feed.
Real-time alerts on this author
Get their new articles emailed to you as they are published.
Daily digest on all my authors
Get all your favorite authors’ new articles emailed to you in one daily digest.
View as an RSS Feed
View Douglas Krohn's Comments
The Problem With Somaxon's Silenor
I must admit -- Jason Chew's comments are right on the money, using the thalidomide example. And Dr. Tucker's comments, too, are accurate -- just because a drug has an unintended or unexpected effect does not mean that there isn't valid physiology or pharmacology behind it. Minoxidil, for example, was originally developed for hypertension -- but it really does make your hair grow. Sildenafil (Viagra) was originally for hypertension, too, but it really does help with ED, and even pulmonary arterial hypertension.
With that being said, Silenor is still a drug with little in the way of a future: No matter what its origins may be, it has a significant competetive landscape to deal with, generic alternatives (both of its own molecule and the molecule of other sleep drugs), the gray market of on-line pharmacies, the future challenge of getting prescription benefits managers on board, and the fact that its data is not overwhelmingly good.
Jun 24 01:20 PM
Link to Comment
Xignite quote data
© 2014 Seeking Alpha